The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.

ABSTRACT:

Background

Vortioxetine is the first mixed serotonin agonist and antagonist antidepressant approved in the US. We sought to evaluate all published and unpublished data available to determine the efficacy and harms of vortioxetine in adults with major depressive disorder.

Methods

We used a predefined search strategy of MEDLINE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Drugs@FDA to identify studies evaluating vortioxetine in the acute treatment of major depressive disorder. Only randomized controlled trials (RCTs) that provided results on relevant clinical efficacy and safety outcomes were included. Study quality was assessed and results were pooled using mixed effect meta-analyses where applicable.

Results

We identified 11 RCTs with 6

SUBMITTER: Meeker AS 

PROVIDER: S-EPMC4351824 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature